ABUS icon

Arbutus Biopharma
ABUS

Overview Fund Activity

144 hedge funds and large institutions have $389M invested in Arbutus Biopharma in 2024 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 47 increasing their positions, 32 reducing their positions, and 11 closing their positions.

Holders
144
Holders Change
+14
Holders Change %
+10.77%
% of All Funds
2.08%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.06%
New
28
Increased
47
Reduced
32
Closed
11
Calls
$9.3M
Puts
$2.17M
Net Calls
+$7.13M
Net Calls Change
-$2.63M

Top Buyers

1
Vanguard Group
1
Vanguard Group
Pennsylvania
$34.3M
2
State Street
2
State Street
Massachusetts
$17M
3
Charles Schwab
3
Charles Schwab
California
$4.67M
4
Morgan Stanley
4
Morgan Stanley
New York
$83.6M
5
BlackRock
5
BlackRock
New York
$47M

Top Sellers

1
ACM
1
ADAR1 Capital Management
Texas
$8.04M
2
Citigroup
2
Citigroup
New York
$420K
3
Hudson Bay Capital Management
3
Hudson Bay Capital Management
Connecticut
$3.97M
4
Susquehanna International Group
4
Susquehanna International Group
Pennsylvania
$404K
5
WP
5
Woodline Partners
California
$2.57M
Name Holding Trade Value Shares
Change 		Shares
Change %
KAS
151
Kestra Advisory Services
Texas
– -$33.4K -10,800 Closed
C
152
Covestor
United Kingdom
– -$21K -6,700 Closed
FIA
153
FNY Investment Advisers
New York
– -$11K -3,800 Closed
OWA
154
Opal Wealth Advisors
New York
– -$309 -100 Closed
CTC
155
Central Trust Company
Missouri
– -$309 -100 Closed
3 4 5 6
7